Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company’s False and Misleading Claims
SVAPALO ALTO, Calif.--(BUSINESS WIRE)--Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8% shareholder in Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), today sent a letter to shareholders. *** Dear Fellow Sinovac Shareholders, We, Vivo Capital (“Vivo”), write to you as fellow shareholders of Sinovac Biotech Ltd. (“Sinovac” or the “Company”) to address a number of statements in the April 29, 20
June 11, 2025Lawsuits
Read more →